C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics
Executive Summary
In an encouraging sign for drug/diagnostic co-development, the independently funded C-Path Institute is now engaging more than 20 pharma and diagnostics companies with interests in non-small-cell lung cancer treatment using EGF receptor-targeted drugs and diagnostics. This proposed initiative could forge a template for future FDA reviews of drugs and companion diagnostics.
You may also be interested in...
New Initiatives to Improve Diagnostic Data Access
A welcome side-effect of the recent pharma trend towards streamlining, outsourcing, and establishing collaborative network strategies is the increasing availability of data and resources that others can draw upon more easily. The phenomenon is encouraging the formation of precompetitive alliances, often diagnostics focused, especially in oncology, where the vast majority of biomarker work has occurred.
New Initiatives to Improve Diagnostic Data Access
A welcome side-effect of the recent pharma trend towards streamlining, outsourcing, and establishing collaborative network strategies is the increasing availability of data and resources that others can draw upon more easily. The phenomenon is encouraging the formation of precompetitive alliances, often diagnostics focused, especially in oncology, where the vast majority of biomarker work has occurred.
A Critical Test for FDA's Critical Path Initiative
FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.